Nivolumab for malignant transformation of ovarian mature cystic teratoma

Kayoko Yoshimura; Koji Yamanoi; Masashi Kanai; Asuka Okunomiya; Yusuke Sagae; Masumi Sunada; Mana Taki; Masayo Ukita; Yoshitsugu Chigusa; Akihito Horie; Ken Yamaguchi; Junzo Hamanishi; Sachiko Minamiguchi; Noboru Yamamoto; Manabu Muto; Masaki Mandai

doi:10.1016/j.gore.2022.101115

Nivolumab for malignant transformation of ovarian mature cystic teratoma

Gynecol Oncol Rep. 2022 Dec 10:44:101115. doi: 10.1016/j.gore.2022.101115. eCollection 2022 Dec.

Authors

Affiliations

¹ Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto City, Kyoto 606-8507, Japan.
² Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto City, Kyoto 606-8507, Japan.
³ Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto Univerisy, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto City, Kyoto 606-8507, Japan.
⁴ Department of Experimental Therapeutics, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.

Abstract

Mature cystic teratoma of the ovary (MCT) occasionally undergoes malignant transformation (MT) that is resistant to chemotherapy and has a poor prognosis. We experienced a case of clinically aggressive MCT-MT that invades surrounding organs and tissues. Although tumor was resected entirely, a rapid tumor recurrence occurred during postoperative chemotherapy (paclitaxel + ifosfamide + cisplatin). The results of comprehensive genomic profiling test performed early in the postoperative period showed a high tumor mutational burden of 23 mutations/Mb. Treatment with nivolumab monotherapy has promptly been initiated and has been very successful for more than one year.

Keywords: Comprehensive genomic profiling test; Immune checkpoint inhibitor; Malignant transformation of mature cystic teratoma; PD-L1; Tumor mutation burden.

Publication types

Case Reports